Interleukin-8 Antibodies

Interleukin-8 (CXCL8)

IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. Additionally it is involved in neutrophil activation.

It's released from several cell types in response to an inflammatory stimulus. IL-8(6-77) includes a 5-10-fold higher action on neutrophil activation, IL-8(5-77) has increased action on neutrophil activation and IL-8(7-77) has a greater affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.

Gene Information

Human
Gene Name:	CXCL8
Uniprot:	P10145
Entrez:	3576

Family

Belongs to:
intercrine alpha (chemokine CxC) family

Alternative Names

3-10C; AMCF-I; C-X-C motif chemokine 8; CXCL8; CXCL8SCYB8; Emoctakin; GCP1; GCP-1TSG-1; IL8; IL-8; interleukin 8; K60; LAI; LECT; LUCT; LYNAP; MDNCF; MDNCFb-ENAP; member 8; MONAP; MONAPGCP1; NAF; NAP1; NAP-1NAP1; NCF; Neutrophil-activating protein 1; Protein 3-10C; T cell chemotactic factor; T-cell chemotactic factor; TCF; TSG1

Molecular Weight

Mass (kDA):
11.098 kDA

Genomic Context

Human
Location:	4q13.3
Sequence:	4; NC_000004.12 (73740569..73743716)

Subcellular Localizations

Secreted.

Diseases

• Inflammation
• Malignant Neoplasms
• Inflammatory Response
• Neoplasms
• Tissue Adhesions
• Carcinoma
• Tumor Angiogenesis
• Lung Diseases
• Infective Disorder
• Fibrosis
• Asthma
• Atherosclerosis
• Chronic Obstructive Airway Disease

• Cell Invasion
• Neoplasm Metastasis
• Arthritis
• Pneumonia
• Pathologic Neovascularization
• Innate Immune Response
• Lung Diseases, Obstructive

Interacting Proteins

• CXCR2
• PF4
• TNFAIP6

Pathways

• Secretion
• Pathogenesis
• Inflammatory Response
• Immune Response
• Angiogenesis
• Cytokine Production
• Cell Proliferation
• Chemotaxis
• Innate Immune Response
• Cell Activation
• Cell Adhesion
• Cytokine Secretion
• Cell Growth

• Cell Death
• Cell Migration
• Virulence
• Localization
• Cell Cycle
• Phagocytosis
• Wound Healing

PTMs

• Phosphorylation
• Acetylation
• Methylation
• Cleavage
• Oxidation
• Reduction
• Nitration
• Glycosylation
• Carboxylation

• Citrullination
• Ubiquitination
• Sulphation
• Demethylation
• Nitrosylation
• Dephosphorylation
• Biotinylation
• Deacetylation
• Myristoylation

Research Areas

• Angiogenesis
• Cancer
• Chemokines and Cytokines
• Cytokine Research
• Immunology

• Innate Immunity
• Signal Transduction

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CXCL8

Best Uses Of The CXCL8 Marker From Boster Bio

If you've ever thought of purchasing a CXCL8 antibody then you're in the right location. Boster Bio offers a high-affinity primary antibody that targets the CXCL8 molecule. It can be utilized in various research projects like species studies and other samples. Plus, you'll earn credits for your research!

Anti-IL8

Anti-IL8 antibodies offer numerous advantages over standard markers. CXCL8 is produced by monocytes and activated macrophages and is highly specific for the neutrophil chemotactic factor (MNCF). It is also a potent inducer of VEGF angiogenesis, vascularization, and the invasiveness of tumor cells. The Boster Bio CXCL8 marker is an anti-IL8 antibody and is highly sensitive to test for inflammatory diseases.

Interleukin-8 (IL-8), known as a chemokine, is a chemokine produced by immune cells. It regulates activity a number of other types of cells. The presence of high levels in cancer tissues can reveal the nature of the response of a tumor. The antigen is produced in the tumor cells and is involved in angiogenesis, recruitment of immune suppressive cells, and the epithelial-to-mesenchymal transition, which is a precursor to metastasis.

HuMax-IL8 monotherapy results indicated that the levels of IL-8 in serum were reduced significantly on day 3 of treatment in comparison to baseline. Serum IL-8 levels decreased at all dose levels. Patients' contributions and the efforts of research staff assisted in the clinical trial. In addition, Morgan Gargulak, Debra Weingarten and Judith Levine contributed to the study.

The CXCL8 antibody is present in various body fluids and cells. Boster Bio's CXCL8 antibody is anti-IL8. It is used to stain intracellular cells and sandwich ELISA and western blot. The CXCL8 antibody was originally designed to be used in MRI. It can also be used with sandwich ELISA or ELISA antibodies.

HuMax-IL8 is safe and has demonstrated positive reversal effects in triple negative breast cancer models both in the laboratory and in vivo. HuMax-IL8 significantly reduced the recruitment of polymorphonuclear MDSCs to the tumor site. HuMax-IL8 also increased breast cancer cells' susceptibility to lysis by immune system.

Anti-CXCL8

The Anti-CXCL8 marker in the Boster bio catalog is a monoclonal anti-mouse antibody with a high affinity for this target. The antibody is validated on several assays, including Western Blotting, Immunohistochemistry, and ELISA. This allows researchers around the world to use it with confidence, and to submit their results to many different applications. The antibody is also compatible with Boster Bio's Bio-Rad system for quantitative immunohistochemistry.

CXCL8 promotes the epithelial-mesenchymal transition (EMT) and autocrine/paracrine EMT. EMT stimulates metastatic and stem cell properties in tumor cells , and increases their capacity to meetastasize. CXCL8 is a potential target for cancer therapies. It could also be a co-target for other targeted therapies.

CXCL8's crystal arrangement was discovered in 1991. It has three antiparallel, nonparallel b-strands and an A-helix. The C-terminal part is comprised of residues 57-72. The structure is stabilized by two disulfide bonds. CXCL8 is a specific type of CXC chemokine. It also has dimers. The monomer is highly affinity to the CXCR1 receptor.

CXCL8 transmits signals through extracellular binding of G-protein-coupled regulators. CXCR1 & CXCR2 share 76% of their sequence homology, however their extracellular loops differ. CXCR2 has a greater functional G-protein-mediated interaction with other ELR positive chemicals, whereas CXCR1 has only a weak affinity for them.

CXCL8 activates several G signaling pathways mediated by proteins. CXCR2 is activated when a receptor binds to it. It stimulates the activity focal adhesionkinases, such as protein phosphatase 2. This phosphorylates receptors , which assists in dephosphorylation. CXCL8 and CXCR2 are essential components of Chemotaxis as well as polarization.

Primary antibody with high affinity

The CXCL8 marker is a chemokine that is expressed by different tissues. The CXCL8 marker is an important part of the inflammatory response. CXCL8 is an ELR+CXC family. The antibody LY3041658 recognizes CXCL8 by its polymorphic conformation. It can bind diverse sequences CXCL8 using conserved residues within the ELR motif.

A high-affinity primary antibody for the CXCL8 marker is suitable for use in immunohistochemical, western blot and ELISA assays. The anti-ovine CXCL8 antibody (clone C9) has been validated for use in immunohistochemistry and western blotting. It also has excellent performance for intracellular staining. This study shows that the antibody can bind to IL-8 and has an excellent affinity.

The discovery of the CXCL8 marker is an promising step towards the creation of new diagnostics for CRC. The marker was discovered by the analysis of transcription profiles and PPI networks from a large clinical population. The researchers discovered that CXCL8 plays a role in the progression of CRC. It also regulates the expression of CREB1, RPS6KB1, and BAD.

A unique, high-affinity primary antibody against the CXCL8 marker has been created. It is a versatile drug candidate that could be utilized for research in immunology or cancer research. A recent study reports that the antibody LY3041658 can bind to all seven human ELR+CXC chemokines with sub-nM affinity. Its biophysical properties have been optimized to enhance its affinity and neutralize its receptor signaling.

To further analyze we applied analytical hydrophobic interaction analysis (HILIC) for determining the hydrophobicity of these antibodies. To do this we used a 15PHE 4.6 100 millimeter column in an Agilent 1100 series HPLC system. The antibodies were diluted to 0.5 mg/mL using PBS pH 7.2. Injection of 0.05mg of antibody into PBS pH7.2. The elution was performed using the linear gradient of 0% to 100% B for 13 minutes. The chromatograms were then analyzed by UV absorption at 280 numer.

Clinical applications

Patients suffering from neurosyphilis have recently been discovered to have the CXCL8 marker in their blood. CXCL8 levels in neurosyphilis patients' CSF are three times higher than those in healthy people. CXCL8 is expressed in different cells than CXCL9 and CXCL7. This is not alarming.

The innate response of the body is affected by the expression of CXCL8 Cell signaling molecule that mobilizes PMN to the lungs. Cancer cells release CXCL8 in response to a variety of external stimuli. Lung macrophages release CXCL8 when they are triggered by inflammation signals. This promotes the migration of PMN into the lung. The progression of various types of cancer is influenced by the CXCR8-CXCR1/2 connection. Additionally, CXCR1/2 is associated with the growth of cancer stem cells.

The CXCL8-CXCR2 axis is an important mediator of inflammation responses. CXCR2-mediated neutrophil recruit is critical to clear lungs that are infected. Mice deficient in CXCR2 are severely hypoxic throughout the course of pulmonary aspergillosis. CXCR2mice also show abnormal neutrophil chemotaxis, which is a hallmark of this signaling pathway.

The CXCL8-CXCR2-axis has been linked to a variety of inflammation-related conditions. It could also be a biomarker that is independent for patients receiving immunotherapy drugs. However the use of this axis for cancer patients requires careful analysis. How does this biomarker function? What clinical applications can the CXCL8 marker be employed for? There are many ways CXCR8/CXCR2 can help in cancer research.

Applications in cancer research

CXCL8 is a biomarker which can be used to determine the likelihood of cancer and relapse. Tumor-derived MDSCs were more abundant in CXCL8 and increased expression of CXCR1. The expression of CXCR1 and CXCL8 is associated with the development of pancreatic cancer. Exogenous CXCL8 was also associated with an increase in pancreatic cancer cell invasion, tumorsphere formation, and increase the CSC population. This effect was reversed by treatment with CXCR1-blocking monoclonal antibody.

Studies have demonstrated that CXCL8 plays a role in tumourigenesis, as it induces myeloid-derived suppressor cells, which are associated with the suppression of immune cells. It connects to G-protein-coupled receptors (GPCRs), and induces phosphorylation of Akt and PKC. It is also important in the development and survival of tumour cells.

In tumourigenesis, the CXCL8/CXCR1/2 pathway of signalling was extensively investigated. The CXCL8/CXCR1/2 network is involved in the growth of tumor cells via angiogenesis, activation of the matrix metaloproteinase as well as metastasis-related tissue remodeling. The CXCL8 signalling system influences tumor cells' response to chemotherapy through altering pathways that are connected with apoptosis as well as multidrug resistance. High levels of CXCL8 are associated with the risk of developing cancer and poor prognosis for cancer patients.

CXCL8 can also be utilized in cancer biology to detect CSCs and cancer cell types. Recent research revealed that tumor cells that express CXCL8 are more effective in forming mammospheres after being treated with Paclitaxel. This study also identified that CXCR1 inhibitors significantly reduced CSC percentage. These findings suggest the possibility of developing new therapeutic targets. Although the research was mostly preclinical, the results suggest that the CXCL8 - CXCR1/2 axis is an effective therapeutic target.